Display options
Cite
Murphy CC, Cirillo PM, Krigbaum NY, et al. In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring. Am J Obstet Gynecol. 2021;226(1):132.e1-132.e14doi: 10.1016/j.ajog.2021.10.035.
Murphy, C. C., Cirillo, P. M., Krigbaum, N. Y., & Cohn, B. A. (2022). In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring. American journal of obstetrics and gynecology, 226(1), 132.e1-132.e14. https://doi.org/10.1016/j.ajog.2021.10.035
Murphy, Caitlin C, et al. "In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring." American journal of obstetrics and gynecology vol. 226,1 (2022): 132.e1-132.e14. doi: https://doi.org/10.1016/j.ajog.2021.10.035
Murphy CC, Cirillo PM, Krigbaum NY, Cohn BA. In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring. Am J Obstet Gynecol. 2022 Jan;226(1):132.e1-132.e14. doi: 10.1016/j.ajog.2021.10.035. Epub 2021 Nov 09. PMID: 34767803; PMCID: PMC8748293.
Copy Download .nbib Format: NLM
Share it on

Am J Obstet Gynecol. 2022 Jan;226(1):132.e1-132.e14. doi: 10.1016/j.ajog.2021.10.035. Epub 2021 Nov 09.

In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring.

American journal of obstetrics and gynecology

Caitlin C Murphy, Piera M Cirillo, Nickilou Y Krigbaum, Barbara A Cohn

Affiliations

  1. School of Public Health, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX. Electronic address: [email protected].
  2. Child Health and Development Studies, Public Health Institute, Berkeley, CA.

PMID: 34767803 PMCID: PMC8748293 DOI: 10.1016/j.ajog.2021.10.035

Abstract

BACKGROUND: 17α-hydroxyprogesterone caproate is a synthetic progestogen initially approved in the 1950s to treat gynecologic and obstetrical conditions. Despite continued concerns about safety and short-term efficacy regarding the use of 17α-hydroxyprogesterone caproate for the prevention of preterm birth in pregnant women, little is known about the long-term effects of 17α-hydroxyprogesterone caproate on the health of the offsprings.

OBJECTIVE: To examine the association between in utero exposure to 17α-hydroxyprogesterone caproate and the risk of cancer in the offspring.

STUDY DESIGN: The Child Health and Development Studies was a population-based cohort of >18,000 mother-child dyads receiving prenatal care in the Kaiser Foundation Health Plan (Oakland, CA) between 1959 and 1966. Clinical information was abstracted from the mothers' medical records beginning 6 months before pregnancy through delivery. We identified the number and timing of 17α-hydroxyprogesterone caproate injections during pregnancy. Incident cancers diagnosed in the offspring were ascertained through 2019 by linkage to the California Cancer Registry. We used the Cox proportional hazard models to estimate the adjusted hazard ratios and their 95% confidence intervals, with the follow-up time accrued from the date of birth through the date of cancer diagnosis, death, or last contact.

RESULTS: A total of 1008 offspring were diagnosed with cancer over 730,817 person-years of follow-up. Approximately 1.0% of the offspring (n=234) were exposed in utero to 17α-hydroxyprogesterone caproate. Exposure in the first trimester was associated with an increased risk of any cancer (adjusted hazard ratio, 2.57; 95% confidence interval, 1.59-4.15), and the risk increased with the number of injections (1-2 injections: adjusted hazard ratio, 1.80; 95% confidence interval, 1.12-2.90; ≥3 injections: adjusted hazard ratio, 3.07; 95% confidence interval, 1.34-7.05). Exposure in the second or third trimester conferred an additional risk for the male (adjusted hazard ratio, 2.59; 95% confidence interval, 1.07-6.28) but not for the female (adjusted hazard ratio, 0.30; 95% confidence interval, 0.04-1.11) offspring. The risk of colorectal (adjusted hazard ratio, 5.51; 95% confidence interval, 1.73-17.59), prostate (adjusted hazard ratio, 5.10; 95% confidence interval, 1.24-21.00), and pediatric brain (adjusted hazard ratio, 34.72; 95% confidence interval, 7.29-164.33) cancer was higher in the offspring first exposed to 17α-hydroxyprogesterone caproate in the first trimester than the offspring not exposed.

CONCLUSION: Caution using 17α-hydroxyprogesterone caproate in early pregnancy is warranted, given the possible link with cancer in the offspring.

Copyright © 2021 Elsevier Inc. All rights reserved.

Keywords: cancer; endocrine disruption; progestogen; risk factor

References

  1. Environ Health Perspect. 2007 Oct;115(10):1406-14 - PubMed
  2. Obstet Gynecol. 1979 Mar;53(3):309-17 - PubMed
  3. Obstet Gynecol. 1985 Jun;65(6):775-80 - PubMed
  4. Akush Ginekol (Mosk). 1981 Jan;(1):53-5 - PubMed
  5. Reprod Sci. 2012 Mar;19(3):290-7 - PubMed
  6. Int J Cancer. 2007 Jul 15;121(2):356-60 - PubMed
  7. J Matern Fetal Neonatal Med. 2021 Apr 29;:1-6 - PubMed
  8. Differentiation. 2018 Sep - Oct;103:24-45 - PubMed
  9. Epidemiol Rev. 2000;22(2):239-48 - PubMed
  10. Asian J Androl. 2006 Jul;8(4):463-7 - PubMed
  11. Semin Perinatol. 2014 Dec;38(8):516-22 - PubMed
  12. Naturwissenschaften. 2003 Jan;90(1):40-3 - PubMed
  13. Teratology. 1987 Feb;35(1):129-36 - PubMed
  14. Diabetes Care. 2007 Sep;30(9):2277-80 - PubMed
  15. Am J Obstet Gynecol. 2011 Mar;204(3):221.e1-8 - PubMed
  16. J Matern Fetal Neonatal Med. 2007 Feb;20(2):89-112 - PubMed
  17. Int J Stat Med Res. 2015;4(3):287-295 - PubMed
  18. Obstet Gynecol. 2007 Oct;110(4):865-72 - PubMed
  19. Clin Gastroenterol Hepatol. 2017 Jun;15(6):903-909.e6 - PubMed
  20. Fertil Steril. 1986 Apr;45(4):575-7 - PubMed
  21. Environ Mol Mutagen. 2019 Jun;60(5):395-403 - PubMed
  22. Am J Obstet Gynecol. 2021 Feb;224(2):175-186 - PubMed
  23. J Obstet Gynaecol Res. 2010 Oct;36(5):929-37 - PubMed
  24. Differentiation. 2021 Mar-Apr;118:4-23 - PubMed
  25. Endocr Rev. 2014 Dec;35(6):961-91 - PubMed
  26. Endocrinology. 2016 Jan;157(1):77-82 - PubMed
  27. Naturwissenschaften. 2004 May;91(5):242-4 - PubMed
  28. JAMA. 2010 May 5;303(17):1723-8 - PubMed
  29. J Steroid Biochem Mol Biol. 2020 May;199:105599 - PubMed
  30. J Clin Endocrinol Metab. 2015 Sep;100(9):3245-50 - PubMed
  31. Lancet. 2021 Mar 27;397(10280):1183-1194 - PubMed
  32. Mol Cell Endocrinol. 2009 May 25;304(1-2):8-18 - PubMed
  33. J Reprod Med. 1999 Feb;44(2 Suppl):148-52 - PubMed
  34. Cancer Causes Control. 2012 Jun;23(6):983-90 - PubMed
  35. JNCI Cancer Spectr. 2019 Jun 28;3(3):pkz045 - PubMed
  36. Am J Epidemiol. 2009 May 15;169(10):1182-90 - PubMed
  37. Environ Health Perspect. 2003 Apr;111(4):389-94 - PubMed
  38. Nat Rev Endocrinol. 2020 Jan;16(1):45-57 - PubMed
  39. Am J Obstet Gynecol. 2013 Jun;208(6):421-6 - PubMed
  40. Fertil Steril. 2008 Feb;89(2 Suppl):e55-6 - PubMed
  41. N Engl J Med. 2003 Jun 12;348(24):2379-85 - PubMed
  42. Endocr Rev. 2015 Dec;36(6):E1-E150 - PubMed
  43. N Engl J Med. 2011 Oct 6;365(14):1304-14 - PubMed
  44. Am J Epidemiol. 1981 May;113(5):563-74 - PubMed
  45. J Matern Fetal Neonatal Med. 2009 Jun;22(6):540-2 - PubMed
  46. Int J Epidemiol. 2005 Dec;34(6):1370-6 - PubMed
  47. Arch Sex Behav. 1984 Oct;13(5):441-55 - PubMed
  48. N Engl J Med. 2007 Aug 2;357(5):454-61 - PubMed
  49. Am J Epidemiol. 1997 Jan 1;145(1):72-80 - PubMed
  50. Birth Defects Res C Embryo Today. 2013 Jun;99(2):134-46 - PubMed
  51. Naturwissenschaften. 2005 Aug;92(8):385-8 - PubMed
  52. J Dev Orig Health Dis. 2021 Aug;12(4):619-626 - PubMed
  53. J Dev Orig Health Dis. 2011;2(6):311-321 - PubMed
  54. Fertil Steril. 1985 Apr;43(4):514-9 - PubMed
  55. N Engl J Med. 1971 Apr 15;284(15):878-81 - PubMed
  56. Am J Public Health. 1989 Mar;79(3):340-9 - PubMed
  57. Calif Med. 1972 Feb;116(2):85-6 - PubMed
  58. Gastroenterology. 2018 Dec;155(6):1716-1719.e4 - PubMed
  59. Best Pract Res Clin Obstet Gynaecol. 2020 Nov;69:13-29 - PubMed
  60. Am J Obstet Gynecol. 2010 Sep;203(3):248.e1-9 - PubMed
  61. Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1826-1833 - PubMed
  62. N Engl J Med. 2020 Dec 10;383(24):e130 - PubMed
  63. Paediatr Perinat Epidemiol. 1988 Jul;2(3):265-82 - PubMed
  64. Teratology. 1983 Feb;27(1):57-64 - PubMed
  65. N Engl J Med. 2020 Dec 10;383(24):e131 - PubMed
  66. Biol Sex Differ. 2013 Mar 21;4(1):5 - PubMed
  67. Obstet Gynecol. 2009 Jul;114(1):45-49 - PubMed
  68. Teratology. 1983 Oct;28(2):201-8 - PubMed
  69. Lancet Public Health. 2019 Mar;4(3):e137-e147 - PubMed
  70. Am J Obstet Gynecol. 2012 Nov;207(5):398.e1-8 - PubMed
  71. N Engl J Med. 1977 Jan 13;296(2):67-70 - PubMed
  72. Drug Metab Dispos. 2010 May;38(5):723-7 - PubMed
  73. Endocr Rev. 2013 Apr;34(2):171-208 - PubMed
  74. Obstet Gynecol. 2009 Feb;113(2 Pt 1):285-92 - PubMed
  75. Lancet. 1983 Sep 3;2(8349):580 - PubMed
  76. IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 - PubMed
  77. Obstet Gynecol. 2020 May;135(5):1207-1213 - PubMed
  78. Obstet Gynecol. 1979 Mar;53(3):300-8 - PubMed
  79. Am J Obstet Gynecol. 1953 Nov;66(5):1062-81 - PubMed
  80. Am J Perinatol. 2020 Jan;37(2):127-136 - PubMed
  81. Arch Sex Behav. 1977 Jul;6(4):257-88 - PubMed

Publication Types

Grant support